Quality of life among Polish Fabry patients - A cross-sectional study quality of life among Polish Fabry patients

Central European Journal of Medicine

Volumn 6, Issue 6, 2011, Pages 741-749

  Żuraw, Wioletta ^a   Golicki, Dominik ^b   Jurecka, Agnieszka ^a,c   Tylki Szymańska, Anna ^a  

^a CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c UNIVERSITY OF GDA SK   (Poland)

Author keywords

EQ 5D; Fabry disease; Quality of life; SF 36

Indexed keywords

ALPHA GALACTOSIDASE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ENZYME REPLACEMENT; FABRY DISEASE; FEMALE; HEALTH STATUS; HUMAN; MALE; MENTAL HEALTH; PAIN; POLAND; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SEX DIFFERENCE; SHORT FORM 36; SOCIAL INTERACTION; VISUAL ANALOG SCALE;

EID: 81355137901     PISSN: 18951058     EISSN: 16443640     Source Type: Journal    
DOI: 10.2478/s11536-011-0087-0     Document Type: Article

References (23)

1. Desnick RJ, Ioannou YA, Eng CM. a-Galactosidase Deficiency; Fabry Disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Vogelstein B (eds). The Metabolic & Molecular Bases of Inherited Disease, New York, The McGraw-Hill Companies Inc., 2001:3733-3774
2. K.F. Gold G.M. Pastores M.F. Botteman J.M. Yeh S. Sweeney W. Aliski C.L. Pashos 2002 Quality of life of patients with Fabry disease Qual Life Res 11 317 327 12086117 10.1023/A:1015511908710 1:STN:280:DC%2BD38zktlegsA%3D%3D (Pubitemid 34596854)
3. W.R. Wilcox J.P. Oliveira R.J. Hopkin A. Ortiz M. Banikazemi U. Feldt-Rasmussen K. Sims S. Waldek G.M. Pastores P. Lee C.M. Eng L. Marodi K.E. Stanford F. Breunig C. Wanner D.G. Warnock R.M. Lemay D.P. Germain 2008 Fabry Registry. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry Mol Genet Metab 93 112 128 18037317 10.1016/j.ymgme.2007.09.013 1:CAS:528:DC%2BD1cXit1Sgsr0%3D
4. D. Bryant H. Schunemann J. Brozek, et al. 2007 Patient reported outcomes: general principles of development and interpretability Pol Arch Med Wewn. 117 125 131
5. R. Schiffmann 2007 Enzyme Replacement in Fabry Disease: The Essence Is in the Kidney Ann Intern Med 146 142 144 17179053 (Pubitemid 351640016)
6. D.L. Patrick R.A. Deyo 1989 Generic and disease-specific measures in assessing health status and quality of life Med Care 27 S217 232 2646490 10.1097/00005650-198903001-00018 1:STN:280:DyaL1M7lvVehtg%3D%3D
7. The Euroqol Group. 1990 EuroQol-a new facility for the measurement of health-related quality of life Health Policy 16 199 208 10.1016/0168-8510(90) 90421-9
8. D. Golicki M. Niewada M. Jakubczyk W. Wrona T. Hermanowski 2010 Self-assessed health status in Poland: EQ-5D findings from the Polish valuation study Pol Arch Med Wewn. 120 276 281 20693958
9. D. Golicki M. Jakubczyk M. Niewada W. Wrona J.J. Busschbach 2010 Valuation of EQ-5D Health States in Poland: First TTO-Based Social Value Set in Central and Eastern Europe Value Health 13 289 297 19744296 10.1111/j.1524-4733. 2009.00596.x
10. C.A. McHorney J.E. Ware J.F. Lu C.D. Sherbourne 1994 The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups Med Care 32 40 66 8277801 10.1097/00005650-199401000-00004 1:STN:280:DyaK2c7gsVeltQ%3D%3D
11. M. Sullivan J. Karlsson J.E. Ware 1995 The Swedish SF-36 Health Survey - I. Evaluation of data quality, scaling assumptions, reliability and construct validity across general populations in Sweden Soc Sci Med 41 1349 1358 8560302 10.1016/0277-9536(95)00125-Q 1:STN:280:DyaK287jtFygsg%3D%3D
12. Ware JE, Kosinski M. SF-36 Physical and Mental Health Summary Scales. In: Lincoln RI, editor. A Manual for Users of Version 1, QualityMetric Inc, 2001
13. StatsDirect Ltd. 2008 StatsDirect statistical software StatsDirect Ltd. England StatsDirect Ltd. StatsDirect statistical software. http://www. statsdirect.com. England: StatsDirect Ltd. 2008
14. R.Y. Wang A. Lelis J. Mirocha W.R. Wilcox 2007 Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life Genet Med 9 34 45 17224688 10.1097/GIM.0b013e31802d8321 1:CAS:528:DC%2BD2sXlt1eit7Y%3D (Pubitemid 46115959)
15. B. Hoffmann A. Garcia de Lorenzo A. Mehta M. Beck U. Widmer R. Ricci 2005 FOS European Investigators. Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey) J Med Genet. 42 247 252 15744039 10.1136/jmg.2004.025791 1:CAS:528:DC%2BD2MXjtVertr8%3D (Pubitemid 40380306)
16. T. Watt A.P. Burlina C. Cazzorla D. Schönfeld M. Banikazemi R.J. Hopkin A.M. Martins K. Sims D. Beitner-Johnson F. O'Brien U. Feldt-Rasmussen 2010 Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: findings from the Fabry Registry Genet Med 12 703 712 20885332 1:CAS:528:DC%2BC3cXhsVWhur3E
17. M. Beck R. Ricci U. Widmer F. Dehout A.G. de Lorenzo C. Kampmann A. Linhart G. Sunder-Plassmann G. Houge U. Ramaswami A. Gal A. Mehta 2004 Fabry disease: overall effects of agalsidase alfa treatment Eur J Clin Invest 34 838 844 15606727 10.1111/j.1365-2362.2004.01424.x 1:STN:280:DC%2BD2cnjtFyksA%3D%3D (Pubitemid 39657931)
18. B. Hoffmann A.G. de Lorenzo A. Mehta M. Beck U. Widmer R. Ricci 2005 FOS European Investigators. Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey) J Med Genet 42 247 252 15744039 10.1136/jmg.2004.025791 1:CAS:528:DC%2BD2MXjtVertr8%3D (Pubitemid 40380306)
19. A. Mehta M. Beck P. Elliott R. Giugliani A. Linhart G. Sunder-Plassmann R. Schiffmann F. Barbey M. Ries J.T. Clarke 2009 Fabry Outcome Survey investigators. Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data Lancet 374 1986 1996 19959221 10.1016/S0140-6736(09)61493-8 1:CAS:528:DC%2BD1MXhsFGgtLrN
20. B. Hoffmann M. Schwarz A. Mehta S. Keshav 2007 On behalf of the Fabry Outcome Survey European Investigators: Gastrointestinal Symptoms in 342 Patients With Fabry Disease: Prevalence and Response to Enzyme Replacement Therapy Clin Gastrol Hepatol 5 1447 1453 10.1016/j.cgh.2007.08.012 (Pubitemid 350181595)
21. A.H. Miners A. Holmes L. Sherr C. Jenkinson K.D. MacDermot 2002 Assessment of health-related quality-of-life in males with Anderson Fabry Disease before therapeutic intervention Qual Life Res 11 127 133 12018736 10.1023/A:1015009210639 1:STN:280:DC%2BD383nvVWhsA%3D%3D (Pubitemid 34438159)
22. Wille N, Badia X, Bonsel G, Burström K, Cavrini G, Devlin N, Egmar AC, Greiner W, Gusi N, Herdman M, Jelsma J, Kind P, Scalone L, Ravens-Sieberer U. Development of the EQ-5D-Y: a child-friendly version of the EQ-5D. Qual Life Res 2010 Apr 20. [Epub ahead of print]
23. Ravens-Sieberer U, Wille N, Badia X, Bonsel G, Burström K, Cavrini G, Devlin N, Egmar AC, Gusi N, Herdman M, Jelsma J, Kind P, Olivares PR, Scalone L, Greiner W. Feasibility, reliability, and validity of the EQ-5D-Y: results from a multinational study. Qual Life Res 2010 Apr 17. [Epub ahead of print]